Ventyx Biosciences Q2 EPS $(0.91) Misses $(0.71) Estimate
Portfolio Pulse from Benzinga Newsdesk
Ventyx Biosciences reported Q2 losses of $0.91 per share, missing the analyst consensus estimate of $0.71 by 28.17%. This represents a 133.33% increase in losses compared to the same period last year.
August 10, 2023 | 8:04 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ventyx Biosciences reported a larger than expected loss for Q2, with EPS of $0.91, missing the estimate of $0.71. This is a significant increase in losses compared to the same period last year.
Ventyx Biosciences reported a larger than expected loss for Q2, which is likely to negatively impact investor sentiment and potentially the stock price in the short term. The significant increase in losses YoY further compounds this negative outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100